BioXcel Therapeutics reports that the U.S. DoD’s CDMRP has awarded a planning grant1 as a part of its Alcohol and Substance Abuse Disorders Research Program (“ASADRP”) related to the development of the Company’s product candidate, BXCL501.
The Company recently announced positive top-line results from its adaptive Phase 1b, randomized, double-blind, placebo-controlled, multi-center, U.S. trial, evaluating multiple doses of BXCL501, an investigational selective and potent alpha2-adrenergic receptor agonist, for acute treatment of agitation in 135 patients with schizophrenia. more